Vatten Pharma & FasterCapital Equitypilot Partnership Accelerates CBD Nanotech to Latin American Medical Markets
SÃO PAULO, Brazil & Dubai, UAE - Jan 03, 2025
Vatten Pharma and FasterCapital today announced a strategic partnership through FasterCapital’s Equitypilot program to accelerate commercialization of VATTEN’s water‑soluble CBD nanotechnology across Latin America. The collaboration pairs FasterCapital’s global acceleration, capital and network with VATTEN’s pharmaceutical R&D, regulatory roadmap and clinical ambitions.
Market opportunity & problem statement
The global medicinal CBD market is rapidly expanding, with Latin America underpenetrated due to quality, dosing variability and physician reluctance. In Brazil and broader LATAM, patients pay premium prices for inconsistent, artisanal products and prescribers (70% reported information gaps) cite contamination and dosing concerns. VATTEN addresses this white space: a pharmaceutical-grade, hydrosoluble CBD offering improved bioavailability and medical credibility where demand, regulatory clarity and import growth converge.
Startup solution & differentiation
VATTEN PHARMA’s Ultra CBD uses nanotech to deliver up to 10x greater absorption versus conventional oils, enabling lower doses, improved safety and consistent pharmacology. Built on pharmaceutical manufacturing controls, purity certification and a scientific evidence program, VATTEN targets prescriber trust through physician education, clinical studies and partnerships with centers of excellence. Initial go-to-market leverages U.S. inventory and phased Brazilian manufacturing with product lines spanning medical, veterinary and cosmetic segments and a prioritized launch in clinical channels.
FasterCapital partnership value
Through Equitypilot, FasterCapital provides structured seed capital, mentorship, go‑to‑market support, regulatory strategy, investor introductions and access to commercialization partners. FasterCapital’s selective criteria prioritize startups with defensible IP, regulatory pathways and scalable models; VATTEN passed these filters based on clinical focus, technology novelty and LATAM market fit. The partnership targets key milestones: Phase‑2 manufacturing set‑up (2025), Phase‑3 clinical evidence and Brazilian registration (2026) and expanded regional launches.
Executive quotes
“[VATTEN PHARMA] represents the kind of deep‑tech, clinically focused company we seek to accelerate strong science, clear regulatory pathway and high market need,” said Hesham Zreik, founding investor and advisor at FasterCapital. “Our Equitypilot resources will compress time to market and de‑risk early commercialization.”
“Physicians and patients need reliable, pharmaceutical‑grade CBD options backed by evidence. FasterCapital’s capital and network let us scale manufacturing, advance clinical trials and build the educational programs prescribers demand,” said Alfredo Bittar CEO of VATTEN PHARMA. “This partnership validates our approach and accelerates access to safer, more effective treatments.”
Growth trajectory & near-term roadmap
Near term VATTEN will finalize Brazilian manufacturing plans, deploy a specialized medical sales force, and initiate Phase‑3 clinical studies while expanding U.S. and EU online sales. Funding rounds guided by FasterCapital will support R&D, regulatory filings, and market rollouts to Mexico and LATAM. Long‑term, VATTEN aims to be a market leader in pharmaceutical CBD formulations and to broaden its pipeline into adjacent CNS and pain indications.
About VATTEN PHARMA
VATTEN PHARMA is a Latin American pharmaceutical company specializing in technology-driven plant-derived medicines. Pioneering water‑soluble CBD nanotechnology and clinical research, VATTEN focuses on physician adoption, manufacturing quality and evidence-based treatments across human, veterinary and cosmetic lines.
About FasterCapital
FasterCapital is a global venture builder and online incubator dedicated to co-funding and co-founding innovative startups. Established in 2014, we are now #1 venture builder in terms of number of startups that we have helped, money invested and money raised. It supports startups worldwide through various programs, including funding assistance, business development, and technical support. The Equitypilot program is designed to help early-stage startups build scalable solutions with mentorship, strategic guidance, and network support.